The Final Formulation — 12 Compounds, 6 Mechanisms
Spermidine 6mg (autophagy master switch via eIF5A hypusination) + Sulforaphane 30mg (TFEB activation, mTOR-independent) + NMN 500mg (NAD+ → SIRT1 → TFEB + DNA repair)
Ashitaba Extract 300mg (std. to DMC) — GATA transcription factor inhibition, a parallel autophagy pathway independent of TFEB/mTOR. Also selectively kills senescent cells via ferritinophagy (Wang 2024, Redox Biology). The only compound in the stack that operates through the GATA axis.
Urolithin A 500mg (mitophagy + lysophagy — clears damaged mitochondria AND damaged lysosomes) + Melatonin 3–5mg (mitochondrial antioxidant at 100x plasma concentration + SIRT1/AMPK autophagy)
Astaxanthin 12mg (lipid peroxidation, BBB-crossing) + NAC 600mg (glutathione precursor, mild iron chelation) + Vitamin C 1g (glutathione recycling, regenerates vitamin E & astaxanthin)
Taurine 2g (mitochondrial buffer, osmolyte, longevity signal — Science 2023) + Glycine 3g (glutathione synthesis, anti-glycation, collagen support) + Centrophenoxine 500mg (direct lipofuscin reduction — regulatory risk, see Section 3)
1. Formulation Specification
12 CompoundsComplete ingredient manifest with doses, fill weights, and proportional contribution to the total serving size.
| # | Ingredient | Dose | % of Fill | Mechanism | Solubility |
|---|---|---|---|---|---|
| 1 | Glycine | 3,000 mg | 36.8% | Glutathione synthesis, anti-glycation | Water-soluble, sweet taste |
| 2 | Taurine | 2,000 mg | 24.5% | Longevity signal, mitochondrial buffer | Water-soluble, slightly bitter |
| 3 | Vitamin C | 1,000 mg | 12.3% | Antioxidant recycling, glutathione regen | Water-soluble, tart/sour |
| 4 | NAC | 600 mg | 7.4% | Glutathione precursor, iron chelation | Water-soluble, sulfurous/bitter |
| 5 | NMN | 500 mg | 6.1% | NAD+ → SIRT1 → TFEB + DNA repair | Water-soluble, slightly bitter |
| 6 | Urolithin A | 500 mg | 6.1% | Mitophagy + lysophagy | Poorly water-soluble (lipophilic) |
| 7 | Centrophenoxine | 500 mg | 5.9% | Direct lipofuscin reduction | Water-soluble |
| 8 | Ashitaba Extract | 300 mg | 3.5% | GATA TF inhibition + senolytic (DMC) | Partially soluble (spray-dry on maltodextrin) |
| 9 | Sulforaphane | 30 mg | 0.4% | TFEB activation via calcineurin | Water-soluble, pungent |
| 10 | Astaxanthin | 12 mg | 0.1% | Lipid peroxidation prevention, crosses BBB | Lipophilic (fat-soluble) |
| 11 | Spermidine | 6 mg | 0.1% | Autophagy via eIF5A hypusination | Water-soluble |
| 12 | Melatonin | 3–5 mg | 0.1% | Mitochondrial antioxidant + autophagy | Amphiphilic (both) |
| TOTAL ACTIVE | ~8,451 mg | 100% | + excipients, flow agents, flavoring | ||
Fill Weight Reality Check
At ~8.45 grams of active ingredients alone (before excipients, flow agents, or flavoring), this formulation is physically impossible to deliver in a single capsule or even a reasonable number of capsules. A size 000 capsule (the largest standard) holds ~800–1,000mg. That means 10–12 capsules per serving — a non-starter for consumer compliance.
The three bulk ingredients (glycine 3g, taurine 2g, vitamin C 1g) represent 71% of the total fill weight. These drive the format decision.
The Taste Problem
Of the 12 ingredients, four have challenging taste profiles:
- NAC (600mg): Sulfurous, eggy, distinctly unpleasant. This is the #1 taste obstacle. At 600mg in solution, it's noticeable.
- Ashitaba Extract (300mg): Slightly bitter, herbaceous/grassy. Manageable with citrus flavoring. Spray-dried form on maltodextrin carrier is milder than raw extract.
- Sulforaphane (30mg): Pungent/spicy (it's the compound that makes broccoli taste like broccoli). At only 30mg, manageable with flavoring.
- NMN (500mg): Mildly bitter. Masking is straightforward at this dose.
However, two ingredients actually help taste: Glycine is naturally sweet (3g provides meaningful sweetness) and Vitamin C is tart/citrusy (1g provides a natural lemon-like base). The glycine sweetness + citric tartness creates a viable foundation for a citrus-flavored powder.
2. Delivery Format Analysis
4 Formats ComparedThe ~8.45g active fill weight eliminates most standard formats. Here's an honest comparison of every viable delivery method.
| Format | Feasibility | Pros | Cons | Verdict |
|---|---|---|---|---|
| Powder Sachet (Stick Pack) | Ideal | Handles 8.5g+ easily; single daily serving; premium presentation; allows flavoring to mask NAC; glycine sweetness + vitamin C tartness create natural citrus base; lower per-unit cost; fast dissolution | Requires flavoring R&D; consumer must mix; urolithin A & astaxanthin are lipophilic (reduced absorption without fat); less portable than capsules | BEST FIT |
| Hybrid: Powder + 2 Softgels | Ideal | Best of both worlds: water-soluble compounds in powder, fat-soluble (urolithin A + astaxanthin) in oil-based softgels for optimal absorption; melatonin in softgel allows flexible evening timing | More complex manufacturing (two SKUs or co-packaged); slightly higher cost; two dosage forms may confuse consumers | OPTIMAL |
| Capsules Only | Poor | Familiar format; portable; no taste issues; precise dosing | 9–12 capsules per serving; severe pill fatigue; poor consumer compliance; high per-unit cost; capsule shells add weight/cost | NOT VIABLE |
| Topical Cream | Wrong Route | Could potentially deliver astaxanthin, melatonin, vitamin C locally to skin | Cannot systemically deliver 8g+ of compounds through skin; taurine, glycine, NAC, NMN, spermidine won't absorb transdermally at effective doses; completely wrong delivery route for autophagy/lysosomal targets (need systemic distribution) | NO |
Why Hybrid Wins
- Bioavailability: Urolithin A and astaxanthin are lipophilic — they absorb dramatically better in an oil-based softgel than dissolved (or undissolved) in water. Putting them in the powder would waste 60–80% of the dose.
- Timing flexibility: Melatonin should be taken at bedtime, not morning. A separate softgel allows the consumer to take the powder in the morning and the melatonin softgel at night.
- Taste: Removing 515mg of lipophilic compounds from the powder eliminates most insoluble particulates. The Ashitaba extract (300mg) is the only partially-soluble compound remaining in the powder — spray-dried on maltodextrin carrier, it disperses cleanly into a slightly cloudy (not gritty) suspension.
- Market precedent: NOVOS (the leading longevity supplement brand) uses this exact approach: NOVOS Core (powder sachet) + NOVOS Boost (capsules). It's a proven consumer model.
Can the Powder Taste Good?
Yes, with proper formulation. Here's why:
- Glycine (3g) is naturally sweet — about 70% the sweetness of sucrose. At 3g, it provides a meaningful sweet base.
- Vitamin C (1g) provides natural tartness — think lemon/citrus.
- Sweet + tart = natural citrus flavor profile. Add citrus flavoring + small amount of stevia or monk fruit to round it out.
- NAC (600mg) is the challenge. Its sulfurous taste is detectable but can be masked with strong citrus flavoring + cooling agents (menthol). At 600mg in 8–12 oz water, it's dilute enough to manage. Many commercial NAC powders exist and taste acceptable.
- NMN (500mg) is mildly bitter — easily masked by the glycine sweetness.
- Sulforaphane (30mg) is so low-dose it won't be detectable in the flavor profile.
Recommended flavor direction: Lemon-lime or citrus burst. The natural ingredient profile supports this without heavy artificial flavoring. Request flavoring samples from your CMO during the R&D phase — most offer 3–5 flavor iterations before production.
3. Regulatory Status
12 Ingredients AssessedEvery ingredient screened for US dietary supplement legality. One ingredient poses a serious regulatory risk.
| Ingredient | Status | Detail |
|---|---|---|
| Glycine | Clear | Established dietary amino acid. GRAS. No issues. |
| Taurine | Clear | Established dietary amino acid. GRAS. Widely sold at 2g doses. |
| Vitamin C | Clear | Long-established dietary ingredient. No issues at 1g. |
| Melatonin | Clear | Legal dietary supplement in US. Widely sold. 3–5mg standard dose. |
| Astaxanthin | Clear | Established supplement ingredient. Multiple brands at 12mg. No issues. |
| Spermidine | Clear* | Sold as wheat germ extract (spermidineLIFE, etc.). Natural form has regulatory precedent. *Synthetic isolates may need NDI notification. |
| Sulforaphane | Clear | From broccoli seed extract. Widely sold. Avoid disease claims on label. |
| Ashitaba Extract | Clear | Angelica keiskei has long history as traditional Japanese vegetable/food. Ashitaba powder and extracts widely sold as dietary supplements. NOAEL established at 300mg/kg/day in 90-day rat study (PMID: 25576957). Non-genotoxic (negative Ames, chromosome aberration, micronucleus). Note: mild antiplatelet activity — disclose on label for consumers on blood thinners. |
| Urolithin A | GRAS | Timeline's Mitopure has GRAS self-affirmation. Source from GRAS-affirmed supplier. Ensure documentation. |
| NMN | Legal (NDI) | FDA reversed exclusion in Sept 2025. Now lawful as dietary supplement. Supplier MUST have valid NDI notification on file with FDA (SyncoZymes, Kingdomway both have). |
| NAC | Gray → Legal | Technically excluded from supplement definition (pre-existing drug). FDA exercises enforcement discretion — will NOT enforce. Rulemaking expected to finalize by mid-2026 formally allowing NAC. Widely sold by every major brand. |
| Centrophenoxine | HIGH RISK | Unapproved drug in US. Prescribed in Europe/China for dementia. Never FDA-approved. No history of use in food supply. Reputable CMOs may refuse. Quality control across industry is poor (only 1/7 products within ±10% of label claim per 2022 analysis, PMID: 35959800). |
The Centrophenoxine Decision
Centrophenoxine is the only compound with solid evidence for directly reducing existing lipofuscin deposits (Nandy 1978, PMID: 342588). That's why it's in the formulation. However, including it creates three risks:
- Manufacturer rejection: Reputable cGMP facilities may decline the entire project if centrophenoxine is included, to protect their FDA standing.
- FDA scrutiny: If the product gains visibility, FDA could issue a warning letter for inclusion of an unapproved drug ingredient, forcing a recall.
- Liability: As an unapproved drug, it creates product liability exposure that insurance may not cover.
Options:
- Option A — Include it: Accept the risk. Consult a dietary supplement regulatory attorney first (Venable LLP, Covington & Burling). Some nootropic-focused CMOs will work with it.
- Option B — Replace with DMAE: Centrophenoxine is a DMAE ester (it delivers DMAE + pCPA). DMAE bitartrate IS a legal dietary supplement with decades of market history. You lose ~30% of the lipofuscin-reduction potency but eliminate 100% of the regulatory risk. Dose: 350mg DMAE bitartrate.
- Option C — Two-SKU strategy: Launch without centrophenoxine (mass market). Sell centrophenoxine as a separate standalone product through a nootropic-focused channel with appropriate disclaimers.
4. Specialty Ingredient Sourcing
5 Novel IngredientsFive ingredients require specialty sourcing beyond standard commodity suppliers. Your CMO's ability to source these determines whether they can make the product.
Urolithin A (500mg) — Most Expensive Ingredient
Premium source: Mitopure (Timeline/Amazentis) — GRAS self-affirmed, extensive clinical trial backing, but expensive and may require licensing.
Generic sources: Mitora (claims world's largest producer), Maxmedchem — both Chinese suppliers offering >98% purity at lower cost. Verify GRAS documentation from supplier before committing.
Key requirement: Lipophilic — must go in the softgel (oil-based) for bioavailability, not the powder.
NMN (500mg) — Newly Legal, Widely Available
Preferred suppliers: SyncoZymes, Inner Mongolia Kingdomway — both have FDA-acknowledged NDI notifications on file.
Key requirement: MUST verify supplier has valid NDIN (New Dietary Ingredient Notification) acknowledgment from FDA. Without this, your product is technically illegal.
Price trend: Dropped significantly since Sept 2025 FDA legalization. Commodity pricing emerging.
Spermidine (6mg) — Natural vs Synthetic
Natural (safer regulatory path): Wheat germ extract standardized to 1% spermidine. spermidineLIFE and SpermidinePURE (Wuxi Cima Science) are established suppliers. Requires 600mg of extract per 6mg active.
Synthetic (>99% purity): Available from Nutri Avenue (FDA-registered US supplier), Frau Pharma/SEMPREVITAL (Italy). May require NDI notification for synthetic form.
Recommendation: Use wheat germ extract form for regulatory safety. The extra 600mg of extract is negligible in a powder format.
Ashitaba Extract (300mg, std. to DMC) — Sourcing the Right Extract
Critical distinction: Most commercial Ashitaba supplements contain xanthoangelol and 4-hydroxyderricin as major chalcones, with DMC (4,4’-dimethoxychalcone) as a minor component. For the GATA-mediated autophagy mechanism, the extract MUST be standardized to DMC content.
Sources: Japanese Ashitaba powder suppliers (traditional sourcing from Hachijo Island), Maypro Industries (US distributor of Japanese botanical extracts), Sabinsa, or Chinese botanical extract houses with HPLC-verified DMC standardization.
Key requirement: Request CoA specifying DMC content (not just total chalcones). Target: extract standardized to ≥5% DMC, so 300mg extract delivers ≥15mg active DMC. Use spray-dried form on maltodextrin carrier for powder mixability.
Regulatory advantage: Ashitaba is a traditional food plant — much cleaner regulatory path than centrophenoxine.
Centrophenoxine (500mg) — Limited Legitimate Supply
Sources: Chinese bulk API suppliers, some US nootropic ingredient houses. Quality is inconsistent — a 2022 analysis found only 1 in 7 US products within ±10% of label claim.
If proceeding: Require Certificate of Analysis (CoA) from supplier showing >98% purity via HPLC. Third-party verify with independent lab testing.
If replacing with DMAE: DMAE bitartrate is widely available as a commodity supplement ingredient from dozens of suppliers.
5. Contract Manufacturer Rankings
8 CandidatesEight contract manufacturers evaluated for capability, reputation, IP protection, and fit for this specific formulation. Ranked by overall suitability.
Why #1: Formulation-first company. 25% of staff in QC. Develops 500+ new products/year. Their in-house R&D team specializes in complex, novel formulations — exactly what this product requires. 5M+ capsules daily capacity, 14 encapsulation machines, stick pack capability. Manufactured for brands in 30+ countries.
Specialty ingredient capability: HIGH — Experienced with novel/premium ingredients. Best candidate for sourcing urolithin A, NMN, and spermidine.
MOQ: Flexible, case-by-case. Contact for quote.
IP protection: Business model depends on building lasting brand partnerships. NDA + manufacturing agreement standard.
Best for: Complex custom formulations requiring real R&D collaboration.
Why #2: 45+ years in business. Zero product recalls in their entire history. First nutraceutical manufacturer in the US to receive FSSC 22000 certification. 4,000+ custom formulas produced for 500+ brands. Full-service from R&D through fulfillment. Advanced testing (HPLC, FTIR).
Specialty ingredient capability: HIGH — 4,000+ custom formulas means extensive supplier relationships.
MOQ: Not disclosed. Likely higher than Lief due to scale.
IP protection: Strong operational incentive (45 years of reputation). Formal NDA standard.
Best for: Maximum safety/quality assurance. Zero-recall track record is unmatched.
Why #3: The only CMO on this list with a BBB A+ rating. Client testimonials describe them as "the absolute BEST." Full turnkey: R&D, ingredient sourcing, packaging, label design, fulfillment. 120,000+ sq ft across 2 facilities. Explicitly accommodates small test runs.
Specialty ingredient capability: MODERATE-HIGH — Strong formulation team but less documented experience with longevity-specific novel ingredients.
MOQ: Flexible — explicitly offers small test runs. Best for startups
IP protection: Client reviews emphasize trustworthiness and collaboration.
Best for: First production run. Flexibility + BBB rating + small batch capability.
Why #4: Explicitly markets longevity/anti-aging supplement manufacturing as a specialty. Has nootropic-specific infrastructure. Stick pack manufacturing capability — directly relevant for the powder sachet format. In-house micro and analytical labs.
Specialty ingredient capability: HIGH — Anti-aging/longevity is their stated focus area.
MOQ: Not disclosed.
Red flag: Class action lawsuit on record (2016 recall). Research this before engaging.
Best for: Anti-aging/longevity-specific expertise + stick pack format.
Strengths: 50+ years nutraceutical experience. Known for responsive customer service (quotes within 48 hours). Award-winning. Competitive pricing with rapid lead times. Flavoring capabilities for powders.
Red flag: Parent company (TLCC) is publicly traded micro-cap stock — potential financial instability. Some communication complaints.
Best for: Mid-stage brands wanting fast turnaround and competitive pricing.
Strengths: The gold standard. Most certified CMO in the industry. First company ever SSCI-certified (benchmark created by Walmart/GNC). Largest custom CMO in the US. Clients in 39 countries. Operates in both US and Switzerland.
Explicit IP protection: Operates under "contract and appropriate confidentiality and quality agreements." One of the few CMOs to publicly address IP protection.
Dealbreaker: 10,000 unit MOQ — not suitable for first run. Save for scale-up after market validation.
Best for: Scaling to mass market after proving the product. The "graduation" manufacturer.
Strengths: More third-party cGMP verifications than any other CMO. Largest softgel capacity in the US (20 billion/year). Products in 35+ countries. 35+ years in operation.
Relevant for: The softgel component (urolithin A + astaxanthin + melatonin). Could potentially manufacture just the softgels while another CMO handles the powder.
Concern: Very large operation — may not prioritize smaller accounts.
Strengths: Family-owned. Full start-to-finish service. Explicitly offers pilot/small-batch runs for de-risking. Expanding operations (Utah facility expansion 2022).
Concern: Younger company (est. 2014). Smaller scale may mean less leverage with specialty ingredient suppliers. Limited public review data.
Best for: Very small initial test batches at lowest possible cost.
Recommended Engagement Strategy
Phase 1 — R&D & Pilot: Contact Lief Labs (#1) and JW Nutritional (#3) simultaneously. Request quotes for a pilot run (500–1,000 units). Both offer R&D collaboration and flexible MOQs. Compare on: R&D fee, per-unit cost, timeline, and willingness to source the specialty ingredients.
Phase 2 — First Production Run: Award the run to whichever partner performs better in Phase 1. Target 2,500–5,000 units.
Phase 3 — Scale-Up: If market validates, transition to NAI (#6) or Vitaquest (#2) for volume production with gold-standard certifications.
6. IP & Formulation Protection
Critical85–90% of supplement brands use third-party manufacturers, and formulation theft is a real concern. Here's how to protect this product.
Pre-Engagement Checklist
- Execute NDA before sharing the formulation. Every reputable CMO will sign without hesitation. If they resist, walk away. The NDA should cover: formulation details, ingredient ratios, processing methods, and any proprietary know-how.
- Manufacturing agreement must explicitly state: You (brand owner) own the formula IP. Manufacturer cannot use, replicate, or share the formulation. You can port the formula to a different manufacturer at any time. All formulation records belong to you.
- File a provisional patent on the specific combination + ratios before engaging any manufacturer. Cost: ~$1,500–$3,000 with a patent attorney. Provides 12 months of "patent pending" protection. The specific 11-compound combination at these ratios targeting the 5-mechanism anti-lipofuscin pathway is novel enough to have patentability merit.
- Beware of "formula lock-in." If the CMO's R&D team develops/modifies your formula, they may claim co-ownership. Clarify in writing BEFORE R&D begins: any modifications to your base formula remain your IP.
- Never give a CMO equity in exchange for reduced manufacturing costs. This is a common pitch from smaller manufacturers. It gives them a financial interest in your formula and reduces your ability to switch manufacturers.
- Trademark your brand name before launch. File with USPTO. This protects your brand even if a manufacturer copies the formula — they can't use your name, branding, or marketing.
What Can & Cannot Be Patented
Patentable: The specific combination of these 11 compounds at these specific ratios for the specific purpose of anti-lipofuscin/anti-aging activity via the 5-mechanism pathway. Method-of-use patents and composition patents are both viable.
Not patentable: Individual ingredients (they're known), general concept of combining supplements, any single mechanism. The novelty is in the specific synergistic combination.
Recommended: Consult a patent attorney specializing in nutraceuticals/dietary supplements. Firms: Venable LLP, Covington & Burling, or any firm with FDA/FTC supplement practice.
7. Cost Estimates & Timeline
Budget PlanningRealistic cost estimates for bringing this supplement to market, from R&D through first production run.
Total Estimated Investment: First Market-Ready Product
Conservative estimate: $20,000–$40,000 from initial R&D through 2,500 packaged, labeled, consumer-ready units. This includes patent filing, trademark, regulatory attorney, R&D, pilot run, and first production run. Packaging/design handled in-house at zero cost.
Margin Breakdown at Scale (10,000+ units, $99/month retail)
| Cost Category | Per Unit | % of $99 |
|---|---|---|
| COGS (manufacturing) | $3–$5 | ~4–5% |
| Fulfillment & shipping | $5–$8 | ~6–8% |
| Payment processing (Stripe/Shopify) | ~$3 | ~3% |
| Customer acquisition (ads) | $25–$50 | 25–50% |
| Returns & refunds (~5%) | ~$5 | ~5% |
| Overhead (software, hosting, etc.) | $5–$10 | ~8% |
| Net profit per unit (DTC) | $23–$48 | ~23–48% |
Manufacturing gross margin: ~95%. The real cost is customer acquisition, not production. Three strategies to maximize net margin:
- Subscription model: CAC only hits once. Month 1 may break even. Months 2+ yield ~$83/month profit ($99 minus ~$16 COGS/fulfillment/processing). A 6-month subscriber is worth ~$430 in profit on a ~$40 acquisition cost.
- Organic/content marketing: The lipofuscin research, SEO content, YouTube, and community building drive CAC toward zero over time. Your existing research pages are content marketing assets.
- Wholesale: Retailers buy at ~50% retail (~$50/box). Your margin is still ~$45/box with zero CAC, but you lose brand control and direct customer relationship.
Breakeven: At $30 average net profit per unit, breakeven on a $30K investment = ~1,000 units. With subscriptions, this accelerates significantly after month 1.
Retail pricing context: $99/month is competitive with comparable products (NOVOS Core retails at $89/month, Timeline Mitopure at $105/month) while offering significantly more compounds and mechanisms of action.
Production Timeline
Month 1–2: Legal & IP
File provisional patent. Register trademark. Engage regulatory attorney for centrophenoxine decision and label compliance review. Finalize formulation (with or without centrophenoxine).
Month 2–3: CMO Selection
Contact Lief Labs and JW Nutritional. Sign NDAs. Share formulation. Request quotes and timelines. Select partner based on R&D capability, pricing, and ingredient sourcing ability.
Month 3–5: R&D & Formulation
CMO R&D phase: finalize powder blend, develop flavoring (3–5 iterations), source specialty ingredients, run stability testing. Develop softgel formulation in parallel. Approve final taste and dissolution.
Month 5–6: Pilot Run
500-unit pilot production. Test consumer experience (taste, mixability, dissolution time). Run third-party lab testing to verify potency and purity of all 12 actives. Adjust if needed.
Month 6–8: First Production Run
2,500-unit production run. Final packaging and labeling. Quality control testing. Ship to fulfillment. Product is market-ready.
8. Immediate Action Plan
Next StepsThe concrete next steps to turn this research into a real product, ordered by priority and dependency.
Step 1: Make the Centrophenoxine Decision
This is the critical-path decision that everything else depends on. Options:
- A) Include (aggressive): Accept regulatory risk. Limits CMO options. Consult supplement attorney first.
- B) Replace with DMAE bitartrate 350mg (conservative): Legal, widely available. Lose some lipofuscin-specific potency but gain clean regulatory path and full CMO access.
- C) Two products (strategic): Main product without centrophenoxine + standalone centrophenoxine through nootropic channel.
Step 2: File Provisional Patent
Before contacting ANY manufacturer. Costs $1,500–$3,000 with a patent attorney. Covers the specific 11-compound combination, ratios, and the 5-mechanism anti-lipofuscin method of use. Provides 12 months of "patent pending" status. This is your primary IP protection.
Step 3: Contact CMOs
After patent is filed. Reach out to Lief Labs and JW Nutritional simultaneously. Send NDA first, then formulation spec. Request: R&D quote, per-unit pricing at 500/2,500/10,000 units, timeline, and confirmation they can source urolithin A, NMN, and spermidine. Compare responses and select partner.
Step 4: Brand & Packaging
While R&D is in progress: finalize brand name, register trademark, design packaging. Consider the hybrid format presentation: a box containing 30 powder sachets + 30 (or 60) softgels. Clean, premium aesthetic aligned with the longevity/biohacking market.